Molecular Mechanisms of Antiviral Agents Against Dengue Virus

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 Mar 30

PMID 36992414

Authors

Michelle Felicia Lee

Yuan Seng Wu

Chit Laa Poh

Affiliations

Soon will be listed here.

Abstract

Dengue is a major global health threat causing 390 million dengue infections and 25,000 deaths annually. The lack of efficacy of the licensed Dengvaxia vaccine and the absence of a clinically approved antiviral against dengue virus (DENV) drive the urgent demand for the development of novel anti-DENV therapeutics. Various antiviral agents have been developed and investigated for their anti-DENV activities. This review discusses the mechanisms of action employed by various antiviral agents against DENV. The development of host-directed antivirals targeting host receptors and direct-acting antivirals targeting DENV structural and non-structural proteins are reviewed. In addition, the development of antivirals that target different stages during post-infection such as viral replication, viral maturation, and viral assembly are reviewed. Antiviral agents designed based on these molecular mechanisms of action could lead to the discovery and development of novel anti-DENV therapeutics for the treatment of dengue infections. Evaluations of combinations of antiviral drugs with different mechanisms of action could also lead to the development of synergistic drug combinations for the treatment of dengue at any stage of the infection.

Citing Articles

Phytomedical Properties of for Boosting Human Immunity Against Viral Infections.

Srivastava R, Jaiswal N, Kharkwal H, Dubey N, Srivastava R Viruses. 2025; 17(2).

PMID: 40007026 PMC: 11861161. DOI: 10.3390/v17020271.

Efavirenz Repurposing Challenges: A Novel Nanomicelle-Based Antiviral Therapy Against Mosquito-Borne Flaviviruses.

Maldonado S, Fuentes P, Bernabeu E, Bertera F, Opezzo J, Lagomarsino E Pharmaceutics. 2025; 17(2).

PMID: 40006610 PMC: 11859092. DOI: 10.3390/pharmaceutics17020241.

Domperidone inhibits dengue virus infection by targeting the viral envelope protein and nonstructural protein 1.

Kaewjiw N, Thaingtamtanha T, Mehra D, Chawnawa W, Prommool T, Puttikhunt C Sci Rep. 2025; 15(1):3817.

PMID: 39885306 PMC: 11782576. DOI: 10.1038/s41598-025-87146-w.

Exploiting venom toxins in paratransgenesis to prevent mosquito-borne disease.

French S, Da Silva R, Storm J, Wastika C, Cullen I, Have M Parasit Vectors. 2025; 18(1):32.

PMID: 39881388 PMC: 11776213. DOI: 10.1186/s13071-025-06663-9.

Clinical Performance of MAGLUMI Diagnostic Tests for the Automated Detection of Dengue Virus.

Peng B, Fang Z, Li C, Liu K, Wang T, Huang K Viruses. 2025; 17(1).

PMID: 39861895 PMC: 11768712. DOI: 10.3390/v17010106.

References

Castrillon-Betancur J, Urcuqui-Inchima S . Overexpression of miR-484 and miR-744 in Vero cells alters Dengue virus replication. Mem Inst Oswaldo Cruz. 2017; 112(4):281-291. PMC: 5354610. DOI: 10.1590/0074-02760160404. View

Bressanelli S, Stiasny K, Allison S, Stura E, Duquerroy S, Lescar J . Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J. 2004; 23(4):728-38. PMC: 380989. DOI: 10.1038/sj.emboj.7600064. View

Heinz F, Stiasny K . Flaviviruses and flavivirus vaccines. Vaccine. 2012; 30(29):4301-6. DOI: 10.1016/j.vaccine.2011.09.114. View

Frentiu F, Zakir T, Walker T, Popovici J, Pyke A, van den Hurk A . Limited dengue virus replication in field-collected Aedes aegypti mosquitoes infected with Wolbachia. PLoS Negl Trop Dis. 2014; 8(2):e2688. PMC: 3930499. DOI: 10.1371/journal.pntd.0002688. View

Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua M . Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384(9951):1358-65. DOI: 10.1016/S0140-6736(14)61060-6. View

Rothan H, Han H, Ramasamy T, Othman S, Rahman N, Yusof R . Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. BMC Infect Dis. 2012; 12:314. PMC: 3575220. DOI: 10.1186/1471-2334-12-314. View

Zhou Z, Khaliq M, Suk J, Patkar C, Li L, Kuhn R . Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS Chem Biol. 2008; 3(12):765-75. PMC: 2782732. DOI: 10.1021/cb800176t. View

Chu J, Leong P, Ng M . Analysis of the endocytic pathway mediating the infectious entry of mosquito-borne flavivirus West Nile into Aedes albopictus mosquito (C6/36) cells. Virology. 2006; 349(2):463-75. DOI: 10.1016/j.virol.2006.01.022. View

Bhattacharyya S, Zagorska A, Lew E, Shrestha B, Rothlin C, Naughton J . Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe. 2013; 14(2):136-47. PMC: 3779433. DOI: 10.1016/j.chom.2013.07.005. View

10.

Miller S, Kastner S, Krijnse-Locker J, Buhler S, Bartenschlager R . The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner. J Biol Chem. 2007; 282(12):8873-82. DOI: 10.1074/jbc.M609919200. View

11.

Allard P, Leyssen P, Martin M, Bourjot M, Dumontet V, Eydoux C . Antiviral chlorinated daphnane diterpenoid orthoesters from the bark and wood of Trigonostemon cherrieri. Phytochemistry. 2012; 84:160-8. DOI: 10.1016/j.phytochem.2012.07.023. View

12.

Rothan H, Bahrani H, Rahman N, Yusof R . Identification of natural antimicrobial agents to treat dengue infection: In vitro analysis of latarcin peptide activity against dengue virus. BMC Microbiol. 2014; 14:140. PMC: 4073510. DOI: 10.1186/1471-2180-14-140. View

13.

Yu I, Zhang W, Holdaway H, Li L, Kostyuchenko V, Chipman P . Structure of the immature dengue virus at low pH primes proteolytic maturation. Science. 2008; 319(5871):1834-7. DOI: 10.1126/science.1153264. View

14.

Barnard T, Abram Q, Lin Q, Wang A, Sagan S . Molecular Determinants of Flavivirus Virion Assembly. Trends Biochem Sci. 2021; 46(5):378-390. DOI: 10.1016/j.tibs.2020.12.007. View

15.

Li L, Lok S, Yu I, Zhang Y, Kuhn R, Chen J . The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science. 2008; 319(5871):1830-4. DOI: 10.1126/science.1153263. View

16.

Kuhn R, Zhang W, Rossmann M, Pletnev S, Corver J, Lenches E . Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002; 108(5):717-25. PMC: 4152842. DOI: 10.1016/s0092-8674(02)00660-8. View

17.

Flipse J, Diosa-Toro M, Hoornweg T, van de Pol D, Urcuqui-Inchima S, Smit J . Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses. Sci Rep. 2016; 6:29201. PMC: 4933910. DOI: 10.1038/srep29201. View

18.

Lai H, Dou D, Aravapalli S, Teramoto T, Lushington G, Mwania T . Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases. Bioorg Med Chem. 2012; 21(1):102-13. PMC: 3563426. DOI: 10.1016/j.bmc.2012.10.058. View

19.

Holden K, Harris E . Enhancement of dengue virus translation: role of the 3' untranslated region and the terminal 3' stem-loop domain. Virology. 2004; 329(1):119-33. DOI: 10.1016/j.virol.2004.08.004. View

20.

Bujalowski P, Bujalowski W, Choi K . Interactions between the Dengue Virus Polymerase NS5 and Stem-Loop A. J Virol. 2017; 91(11). PMC: 5432874. DOI: 10.1128/JVI.00047-17. View